Pedro Chorão, Marta Henriques, Marta Villalba, Juan Montoro, Aitana Balaguer-Roselló, Eva María González, María Dolores Gómez, Inés Gómez, Pilar Solves, Marta Santiago, Pedro Asensi, Brais Lamas, Ana Bataller, Pablo Granados, Juan Eiris, David Martinez, Alberto Louro, Paula Rebollar, Aurora Perla, Miguel Salavert, Javier de la Rubia, Miguel Ángel Sanz, Jaime Sanz
BACKGROUND: Cytomegalovirus (CMV) reactivations cause significant morbidity in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Graft-versus-host disease prophylaxis (GVHD) with post-transplant cyclophosphamide (PTCy) is associated with an increased risk of CMV infections, with limited data on HSCT with PTCy assessing together matched sibling donors (MSD), matched unrelated donors (MUD), and haploidentical donors (HAPLO). OBJECTIVES: Characterize CMV reactivation and recurrences, in patients with hematologic malignancies undergoing HSCT from MSD, MUD, and HAPLO using PTCy as GVHD prophylaxis in the pre-letermovir era...
February 6, 2024: Transplantation and cellular therapy